What is Maravai LifeSciences Holdings, Inc.'s cygnus — R&D?

Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — R&D of $483K in Q1 2026.

How has Maravai LifeSciences Holdings, Inc.'s cygnus — R&D changed year-over-year?

Maravai LifeSciences Holdings, Inc.'s cygnus — R&D decreased by 17.4% year-over-year, from $585K to $483K.

What does cygnus — R&D mean?

Represents expenditures focused on the innovation, development, and improvement of products within the Biologics Safety Testing segment. This investment is critical for maintaining a competitive edge and ensuring the long-term relevance of the segment's product portfolio. High levels of R&D spending indicate a commitment to future growth and technological leadership.

Maravai LifeSciences Holdings, Inc. MRVI Cygnus — R&D

Other segment segments

TriLink

$2.52M—

Similar metrics at other companies

DELLClient Solutions Group — R&D

$192M+41.2%

QDELR&D

$2.3M-14.8%

TMOAnalytical Instruments — Research and development expenses

$139M+1.5%

QRVOCSG — Research and Development Expense

$27.11M-17.2%

IDXXCAG segment revenue — R&D

$65.79M+11.4%

TMOLife Sciences Solutions — Research and development expenses

$131M-5.8%

Other financials

Income statement

See full

Revenue$65.8M+40.5%

Gross profit$33.7M+336%

Operating income-$2.2M+95.6%

Net income-$3.7M+87.5%

EPS (diluted)-$0.02+90.5%

Balance sheet

See full

Cash & equivalents$165.9M-41.8%

Total debt$270.9M-17.1%

Total equity$211.6M-29.6%

Total assets$713.2M-25.7%

Cash flow

See full

Operating cash flow$8.7M+192%

CapEx$4.4M-1.4%

Free cash flow$4.2M+130%

Valuation

See full

Market cap$902.74M+204%

Enterprise value$1.01B+198%

P/S4.4×+3.2×

Profitability

See full

Gross margin29.3%-8.0pp

Operating margin-82.2%-16.6pp

Net margin-51.1%-9.9pp

FCF margin-25.7%—

Returns & leverage

See full

Return on equity-40.8%-4.0pp

Debt / equity1.3×+0.2×

Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s cygnus — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s cygnus — R&D?: Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — R&D of $483K in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s cygnus — R&D changed year-over-year?: Maravai LifeSciences Holdings, Inc.'s cygnus — R&D decreased by 17.4% year-over-year, from $585K to $483K.
What does cygnus — R&D mean?: Represents expenditures focused on the innovation, development, and improvement of products within the Biologics Safety Testing segment. This investment is critical for maintaining a competitive edge and ensuring the long-term relevance of the segment's product portfolio. High levels of R&D spending indicate a commitment to future growth and technological leadership.